N/A N=51 CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
In-stent Restenosis
Primary: The Primary Safety Endpoint for the CVT-ISR Study: Freedom From Target Lesion Failure (TLF) Rate — 4; 1; 0; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis
In-Stent Restenosis
Primary: Percent Diameter Stenosis (%DS) in the Analysis Segment — 36.0 Percentage stenosis of vessel diameter
N/A N=81 Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis
In-stent Coronary Artery Restenosis
Primary: In-stent Late Lumen Loss — 0.07 mm
N/A N=86 Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels
Coronary Artery Disease
Primary: In Stent Mean Cross-sectional Area of Neo-intimal Tissue Coverage — 1.381; 0.949 mm^2
Phase 3 N=100 Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
Coronary Artery Disease
Primary: Percentage of Participants Who Experienced In-lesion Restenosis as Measured by Quantitative Coronary Angiography (QCA) at 6 Months Post-procedure — 16.9 Percentage of…
N/A N=499 STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
Peripheral Arterial Disease
Primary: Percentage of Participants With Freedom From Device and Procedure-related Death and Freedom From Target Limb Major Amputation and Clinically-driven Target Lesion…
N/A N=15 Coronary Flow Reserve Following Orbital Atherectomy
Coronary Artery Disease
Primary: Coronary Flow Reserve (CFR) — 2.23 Ratio
Phase 2 N=12 Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
Coronary Restenosis
Primary: Phase I: Number of Participants With Dose-limiting Toxicities — 0; 0; 0; 0 participants
Phase 4 N=200 Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents
Coronary Heart Disease · Coronary Restenosis
Primary: Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions. — 5483; 7658.2 US dollars — p=<0.05
Phase 3 N=2,651 Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Coronary Artery Disease · Angina Pectoris
Primary: Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization…
N/A N=222 EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
Coronary Artery Disease (CAD) · Chronic Total Occlusion (CTO)
Primary: Number of Participants With Stent-related: Major Adverse Cardiac Events (MACE) (Per ITT Set) — 39 Participants
N/A N=214 Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques
Stable Angina
Primary: Percentage of Participants With Major Adverse Cardiac Events(MACE) — 1.72; 6.86 percentage of participants
N/A N=1,334 Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
Coronary Artery Disease · Atherosclerosis, Coronary · Myocardial Ischemia
Primary: Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index Procedure by Bayesian Estimation — 6.32; 8.90 Percentage of participants
N/A N=29 JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
N/A N=60 Rotational Atherectomy Combined With Cutting Balloon to Optimize Stent Expansion in Calcified Lesions
Coronary Artery Disease · Atherosclerosis
Primary: Minimum Stent Area After Percutaneous Coronary Intervention — 6.7; 6.9 mm^2
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=108 In-Stent Restenosis Post-Approval Study
Peripheral Artery Disease · Vascular Disease
Primary: Primary Effectiveness — 0.715 Probability
N/A N=56 Resolute Integrity US Extended Length Sub-Study(RI US XL)
Coronary Artery Disease
Primary: Composite Rate of Cardiac Death and Target Vessel Myocardial Infarction (MI) — 4 Participants
N/A N=93 AngioSculpt® Coronary Bifurcation Study
Coronary Artery Disease · Myocardial Ischemia
Primary: Procedural Success — 91.4 percentage of participants
N/A N=75 Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study
Coronary Artery Disease
Primary: In-stent Late Lumen Loss as Measured by Quantitative Coronary Angiography — 0.24 mm
Phase 4 N=20 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging
Peripheral Artery Disease · Vascular Disease · Critical Limb Ischemia
Primary: Change in Percent Wall Volume (PWV) — 12.3; 3.9 Percent Wall Volume — p=0.22
N/A N=1,402 The Medtronic RESOLUTE US Clinical Trial
Coronary Artery Disease
Primary: Target Lesion Failure (TLF) — 4.7 percentage of participants
N/A N=30 Single-centre, Registry Trial, the Patients Presented With Stable Coronary Artery Disease
Coronary Artery Disease
Primary: MLD SB Diameter — 08.; 1.0; 2.3; 2.2 mm
N/A N=30 Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
Coronary Microvascular Dysfunction
Primary: Change in Coronary Flow Reserve (CFR) — 3.04 ratio — p=0.0137
Phase 4 N=888 Clinical Investigation for Everolimus Drug Eluting Stent
Coronary Arterial Disease (CAD)
Primary: 888 Number of Participants With Major Adverse Cardiac Events (MACE) at 30 Days — 0 participants
Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
Phase 3 N=252 Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis
Peripheral Arterial Disease
Primary: Freedom From Target Lesion Revascularization (TLR) — 123; 43 # of participants free from TLR
Phase 4 N=114 Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
CVD
Primary: Number of Participants With Occlusion and Restenosis at One Year — 58; 56 participants
N/A N=100 NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Atherosclerosis · Coronary Artery Disease
Primary: Technical Success Rate — 99.2 percentage of lesions
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio